Supplementary information for

Integrated multi-omics analyses identify anti-viral host factors and pathways controlling

SARS-CoV-2 infection

Jiakai Hou^{1#}, Yanjun Wei^{2#}, Jing Zou^{3#}, Roshni Jaffery¹, Long Sun³, Shaoheng Liang^{2,4,16}, Ningbo Zheng¹, Ashley M. Guerrero¹, Nicholas A. Egan¹, Ritu Bohat¹, Si Chen¹, Caishang Zheng², Xiaobo Mao⁵, S. Stephen Yi^{6,7}, Ken Chen², Daniel J. McGrail⁸, Nidhi Sahni^{2,9}, Pei-Yong Shi^{3,10,11,12,13,14*}, Yiwen Chen^{2,15*}, Xuping Xie^{3,14*}, and Weiyi Peng^{1*}

¹Department of Biology and Biochemistry, University of Houston, Houston, TX.

²Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.

³Department of Biochemistry & Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA.

⁴Department of Computer Science, Rice University, Houston, TX, USA.

⁵Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

⁶Department of Oncology, Livestrong Cancer Institutes, and Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA

⁷Interdisciplinary Life Sciences Graduate Programs (ILSGP) and Oden Institute for Computational Engineering and Sciences (ICES), The University of Texas at Austin, Austin, TX, USA

⁸Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH.

⁹Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ¹⁰Institute for Human Infections and Immunity, The University of Texas Medical Branch, Galveston, TX, USA.

¹¹Sealy Institute for Vaccine Sciences, The University of Texas Medical Branch, Galveston, TX, USA.

¹²Sealy Center for Structural Biology & Molecular Biophysics, The University of Texas Medical Branch, Galveston, TX, USA.

¹³Institute for Translational Science, The University of Texas Medical Branch, Galveston, TX, USA.

¹⁴Sealy Institute for Drug Discovery, The University of Texas Medical Branch, Galveston, TX, USA.

¹⁵Quantitative Sciences Program, MD Anderson Cancer Center, UT Health Graduate School of Biomedical Sciences, Houston, TX, USA


[#]These authors contributed equally

¹⁶Current affiliation: Computational Biology Department, School of Computer Science, Carnegie Mellon University, Pittsburgh PA


***Corresponding Authors:** Weiyi Peng, University of Houston, 3455 Cullen Blvd., Suite 342 Houston, TX 77204-5001, Phone: 713-743-6941, E-mail: <u>wpeng2@Central.uh.edu</u>; Xuping Xie, The University of Texas Medical Branch, 301 University Blvd., Galveston TX 77550, Phone: 409-772-1725, E-mail: <u>xuxie@UTMB.edu</u>; Yiwen Chen, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, Phone: 713-745-9283, E-mail: <u>ychen26@mdanderson.org</u>; Pei-Yong Shi, The University of Texas Medical Branch, 301 University Blvd., Galveston TX 77550, Phone: 409-772-1725, E-mail: <u>peshi@UTMB.edu</u>.

Supplementary information includes

• Supplementary Figure 1-13 and their related figure legends




Supplementary Figure 1. Establishment of genome-wide CRISPR/Cas9 dropout screens for SARS-CoV-2 infection (a) Evaluation of permissiveness of human epithelial cell lines for SARS-CoV-2 infection. Human epithelial cells were infected with recombinant SARS-CoV-2-Nluc at MOI=0.2 and luciferase signals were measured at 24-h post-infection. At least two independent experiments were performed. Data were analyzed using one-way ANOVA followed by Tukey's post hoc test were presented as mean values \pm SD; n = 6 biologically independent samples. (b) Expression of ACE2 and Cas9 expression in A549-AC cells detected by western blot analysis. Anti-human ACE2 and anti-FLAG antibodies were used to determine the level of ACE and FLAGtagged Cas9, respectively. (c) Expression levels of ACE2 and Cas9 in A549-AC cells detected by flow cytometry. The expression of GFP, a surrogate reporter for Cas9, was used to determine Cas9 expression. (d) Dose effect of SARS-CoV-2 on CPE. A549-AC cells were infected with different MOIs (ranging from 0.1 to 40) of recombinant SARS-CoV-2. 48 hours after infection, the viability of infected cells was measured. A four-parameter nonlinear regression method was used to generate the estimated dose-response curve and to calculate the MOI for 50% of cell lysis. (e) Representative images of cells before and after viral infection (scale bar 12.5µm, magnification 400×). Typical bright field images of pooled A549-AC cells with the gRNA library were illustrated before (left panel) and after (right panel) SARS-CoV-2 infection. Samples were triplicated in experiments. The comparisons with statistical significance were indicated. Source data and exact *p*-values are provided in a Source data file. p<0.05; p<0.001; p<0.001; p<0.001.




Supplementary Figure 2. Quality evaluation of results from the genome-wide CRISPR dropout screen. (a) Raw read counts of total gRNAs in samples collected from the genome-wide CRISPR dropout screen. (b) Correlations of gRNA abundance across experimental samples. Pairwise Pearson correlation analyses were performed between two distinct samples. (c) Distribution of gRNAs targeting essential and non-essential genes in the reference sample (upper panel), the control samples (middle panel), and the SARS-CoV-2 infected samples (bottom panel).


JHou et.al Supplementary Figure 3



Supplementary Figure 3. Changes in abundance of gRNAs targeting cohesin-related genes in the SARS-CoV-2 screen. Cohesin-related genes are into two categories: Inscreen (gRNAs targeting genes with statistically significant depletion in the SARS-CoV-2 group) and Others (gRNAs targeting genes without statistically significant depletion in the SARS-CoV-2 group). Boxplots of normalized gRNA counts of each category in three types of samples: the Ref samples, the control samples, and the SARS-CoV-2 samples were shown. Data were analyzed using Wilcoxon signed-rank test and presented as mean values \pm SD; Source data and exact *p*-values are provided in a Source data file. **p*<0.05; ****p*<0.001; *****p*<0.0001.


JHou et.al Supplementary Figure 4







а

Supplementary Figure 4. Phenotypes of knocking out putative host factors in lung epithelial cells. (a) Effects of knocking out putative host factors on CPE at the high MOI condition. A549-AC cell lines expressing related gRNAs were infected with SARS-CoV-2 at MOI=5. The cell viability was measured at 48 hours post-infection. (b) Effects of knocking out putative host factors on *in vitro* growth. Equal numbers of genetically modified A549-AC cells were seeded and cultured for 48 hours *in vitro*. The relative changes in cell numbers of A549-AC cells with gene-specific KO were calculated by normalizing with cell numbers of A549-AC cells expressing non-targeting gRNA. At least two independent experiments were performed. Data were analyzed using one-way ANOVA followed by Dunnett's post hoc test and were presented as mean values \pm SD; n = 3 biologically independent samples. Source data and exact *p*-values are provided in a Source data file. **p*<0.05; ***p*<0.01; ****p*<0.001; ****p*<0.001. n.s., not significant.



Supplementary Figure 5. Comparisons of expression levels of identified host factors in lung epithelial cells from pneumonia patients. The mRNA expression levels of two pro-viral factors (*ATP6V0D1* and *DPAGT1*) and three anti-viral factors (*DAZAP2*, *VTA1*, and *KLF5*) in epithelial cells in bronchoalveolar lavage fluids were extracted from published datasets. Patients were stratified by their diagnosis (COVID-19 and non-COVID-19) and severity (mild and severe). Log-transformed mRNA counts of each host factor in lung epithelial cells from different patient groups were illustrated. The comparisons with statistical significance were indicated in the method. Source data and exact *p*-values are provided in a Source data file. **p*<0.05; ****p*<0.001; *****p*<0.0001.






Empty Vector


ORF




Supplementary Figure 6. Successful gene-specific perturbations in A549-AC cells. (a) Inhibition of gene-of-interests in A549-AC cells by gene-specific gRNAs at mRNA level. (b) Inhibition of gene-of-interests in A549-AC cells by gene-specific gRNAs at protein level. (c) Increased mRNA expression of gene-of-interests in gene-specific overexpression (OE) A549-AC cells. (d) Increased protein expression of gene-of-interests in gene-specific OE A549-AC cells. The comparisons with statistical significance were indicated. At least two independent experiments were performed. Data were analyzed using unpaired T-test with two tails were presented as mean values \pm SD; n = 3 biologically independent samples. Source data and exact *p*-values are provided in a Source data file. ***p<0.001; ****p<0.0001.



H2023-AC








а

Supplementary Figure 7. Successful gene-specific perturbations in H2023-AC and Calu-3-


Cas9 cells. Inhibition of gene-of-interests in H2023-AC cells (a) and Calu-3-Cas9 cells (b) by gene-specific gRNAs at mRNA level were determined by RT-PCR. The comparisons with statistical significance were indicated. At least two independent experiments were performed. Data were analyzed using unpaired T-test with two tails were presented as mean values \pm SD; n = 3 biologically independent samples. Source data and exact *p*-values are provided in a Source data file. ****p*<0.001; *****p*<0.0001.



b

а


Supplementary Figure 8. Effects of perturbation of selected host factors on CPE induced by SARS-CoV-2 in H2023-AC and Calu-3-Cas9 cells. (a-b) Putative five host factors including two pro-viral factors (*ATP6V0D1*, *DPAGT1*) and three anti-viral factors (*DAZAP2*, *VTA1*, *KLF5*) were knocked out in H2023-AC and Calu-3-Cas9 cells. Genetically modified H2023-AC cells (a) and Calu-3-Cas9 cells (b) were infected with recombinant SARS-CoV-2 at MOI=0.5, 2.5, and 5 for 48 hours. H2023-AC and Calu-3-Cas9 cells expressing a non-targeting gRNA (NC) served as control cells. Data were normalized using the viability of corresponding cells at mock conditions. At least two independent experiments were performed. Data were analyzed using one-way ANOVA followed by Dunnett's post hoc test and were presented as mean values \pm SD; n = 3 biologically independent samples. Source data and exact *p*-values are provided in a Source data file. **p*<0.05; ***p*<0.01; ****p*<0.001; ****p*<0.001.



Recombinant SARS-CoV-2 Delta strain


Supplementary Figure 9. Effects of perturbation of selected host factors on CPE induced by the Delta strain of SARS-CoV-2. A549-AC cells with or without genetic KO were infected with recombinant SARS-CoV-2 (Delta strain) at MOI=0.5, 2.5, and 5 for 48 hours. A549-AC cells expressing a non-targeting gRNA (NC) served as control cells. Data were normalized using the viability of corresponding cells at mock conditions. At least two independent experiments were performed. Data were analyzed using one-way ANOVA followed by Dunnett's post hoc test and were presented as mean values \pm SD; n = 3 biologically independent samples. Source data and exact *p*-values are provided in a Source data file. ***p*<0.001; *****p*<0.0001.

8




Supplementary Figure 10. Molecular characterization of DAZAP2 /VTA1/KLF5-KO cells.


(a) PCA analysis reveals distinct transcriptomic profiles among A549-AC with and without genetic KO. (b-d) IPA of results from the unique DEGs among DAZAP2-KO (b), VTA1-KO (c), and KLF5-KO (d) cells. The top 15 enriched canonical pathways displaying statistical significance were listed. *p*-values for each gene set were calculated by using a Right-Tailed Fisher's Exact Test. Source data and exact *p*-values are provided in a Source data file.



Supplementary Figure 11. Levels of *SERPINE1* **expression in lung epithelial cells from COVID-19 patients.** The mRNA expression levels of *SERPINE1* in epithelial cells in bronchoalveolar lavage fluids were extracted from published scRNA-Seq datasets as described in Supplementary Figure 5. The box plot was made by using Log-transformed mRNA counts in lung epithelial cells from different patient groups. The comparisons with statistical significance were indicated in the method.



Supplementary Figure 12. Summary of experimental procedures including screens, integrative analysis, candidate selection, and validation.



Supplementary Figure 13. Gating strategy of flow cytometry.